TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01274260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (0.9%)
Description: The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
Study: NCT03869892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil hydrochloride (S95005)
Description: Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab experimental
Description: Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
Study: NCT03466164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Program
Description: 8 week, 10-session course of mindfulness training
Study: NCT05053542

Intervention type: PROCEDURE
Intervention: Enema
Description: Patients in the PBP group underwent a cleansing enema procedure with a solution of monosodium phosphate and disodium phosphate (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before hemorrhoidectomy, whereas patients in the non-PBP group skipped the procedure.
Study: NCT03355664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24
Study: NCT03584802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchanges
Description: The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment of AE-IPF
Description: Conventional treatment of AE-IPF
Study: NCT03355664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACT
Description: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24
Study: NCT02753244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Based Cognitive Video Games Software
Description: Intendu FBT motion based cognitive video games software

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Based Cognitive Video Games Software
Description: Intendu FBT motion based cognitive video games software

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iPad Apps
Description: Commercially available iPad game applications
Study: NCT02166372

Intervention type: OTHER
Intervention: Observation of natural course of Diabetes Mellitus Type 2
Study: NCT03662243

Intervention type: BEHAVIORAL
Intervention: Multicomponent reading and writing treatment
Description: Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
Study: NCT00885001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short Arc Banding
Description: Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
Study: NCT01230775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide retard
Description: Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Week 1:~1. x1 tablet/d of placebo will be administered in week 1.~   Week 2~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/
Study: NCT02873520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cell Immunotherapy
Description: DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT03749642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone/gabapentin 2.5/25 mg
Description: The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
Study: NCT01618812

Intervention type: PROCEDURE
Intervention: Lateral lengthening osteotomy of calcaneus
Description: Use of artificial bone graft
Study: NCT02296879

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SAIT301
Description: The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
Study: NCT01254955

Intervention type: BIOLOGICAL
Intervention: H1N1 vaccine Pandemrix

Intervention type: BIOLOGICAL
Intervention: H1N1 vaccine Pandemrix
Study: NCT03926546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERP for Individuals
Description: Comparing Group vs. Individual ERP for OCD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERP for Individuals
Description: Comparing Group vs. Individual ERP for OCD
Study: NCT03199339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
Study: NCT01390584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: IV
Study: NCT03749642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone/gabapentin 5/50 mg
Description: The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone/gabapentin 10/100
Description: The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: The total daily doses administered will be:~* 600 mg from day 0 to day 6 (±1)~* 900 mg from day 7 (±1) to day 13 (±1)~* 1200 mg from day 14 (±1) to day 20 (±1)~* 1800 mg from day 21 (±1) to day 56 (±2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Two capsules, three times a day, for 8 weeks.
Study: NCT02385123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine Inactivated
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
Study: NCT01472237

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional intervention
Description: Modification of diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention
Description: Modification of diet
Study: NCT04498910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3451838
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT01108991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity self-management
Description: This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPD education + Usual care
Description: Six weeks of COPD self-management education plus usual care
Study: NCT02557503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and fluorouracil
Description: Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
Study: NCT02756455

Intervention type: OTHER
Intervention: gastric cancer pts undergoing surgery
Description: Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
Study: NCT03869892

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab control
Description: Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
Study: NCT02611440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load.
Study: NCT02649335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Description: Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
Study: NCT04671485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
Study: NCT01390584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: IV
Study: NCT03199339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
Study: NCT01390584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: IV

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET
Description: fludeoxyglucose F 18 Imaging exam

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET
Description: fludeoxyglucose F 18 Imaging exam

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: INRT
Description: selective external radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: INRT
Description: selective external radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: IV
Study: NCT03199339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
Study: NCT00088998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study: NCT01592695

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco quit line referral
Description: Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy - nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01390584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV
Study: NCT00088998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT03398278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Tamper Resistant
Description: Orally taking Oxycodone Tamper Resistant 40mg in fast state

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OXYCONTIN®
Description: Orally taking OXYCONTIN® 40mg in fast state
Study: NCT04671485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autohypnosis
Description: The patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Musicotherapy
Description: the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions
Study: NCT05124405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: wearable activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: wearable activity tracker
Study: NCT05095493

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Acetate
Description: 50 mg tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Acetate
Description: 50 mg tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Zinc Acetate matched placebo tablet
Study: NCT05124405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: wearable activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: wearable activity tracker
Study: NCT01592695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy - nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT02125435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous
Study: NCT05095493

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Zinc Acetate matched placebo tablet